Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Search News Archive

Special Report
PBAC March outcomes in full
In a meeting that saw 22 major medicines submissions, positive and negative results were equally mixed with nine of each plus two deferrals and two no results because of a lack of data from the TGA.
Pipeline Monitor
FDA shoots down Olumiant
The FDA has surprised by rejecting Lilly and Incyte's oral rheumatoid arthritis drug Olumiant, diverging from the EU's approval of the drug in February.
Approvals Action
Keytruda wins another indication
The TGA has revealed the granting of a new indication to MSD's blockbuster cancer drug Keytruda and CSL's new product Afstyla has been approved for treating haemophilia A.